Neurosurgery
Pilitsis Lab
Research Profile
The Pilitsis Lab focuses on advancing functional neurosurgery and neuromodulation to improve outcomes for patients with neurological disorders and chronic pain. Her NIH-sponsored research program integrates both basic and clinical approaches to investigate the mechanisms of chronic pain and optimize neuromodulation therapies. Key areas of study include the development of safer, more effective treatment strategies through device innovation, as well as the integration of robotics, focused ultrasound, and machine learning to enhance precision, personalize care, and improve the overall patient experience.
Huntoon Lab
Research Profile
Dr. Kristin Huntoon’s lab aims to identify more effective treatments for glioblastoma (GBM). Most of these highly aggressive brain tumors contain a genetic alteration in a telomerase gene that allows the cells to divide indefinitely. The Huntoon lab is investigating novel compounds that target telomerase in order to prevent the rapid growth of GBMs. Additionally, they seek to understand whether this drug contributes to the activation of the immune system, and whether that activation subsequently has an effect the ability to remove the tumor entirely after radiation.
Dr. Paul Larson | Telkes Lab
Research Profile:
At the Telkes Lab, we investigate the spine–brain continuum to elucidate the neurophysiological mechanisms that underpin neuromodulation therapies, including spinal cord stimulation and deep brain stimulation. Our work focuses on improving the lives of individuals affected by chronic pain and movement disorders such as Parkinson’s disease and essential tremor.
Clinical Trials
Upcoming
Randomized Study of the pdSTIM™ System (phrenic nerve to diaphragm STIMulation) in Failure to Wean Mechanically Ventilated Patients (ReInvigorate Study); PI Dr. Julie Pilitsis
Exploring candidate biosignals to optimize Spinal Cord Stimulation therapy; PI Dr. Julie Pilitsis
Active
| RNDP-001-02SS: A Screening Study Assessing Eligibility of Idiopathic Parkinson’s Disease Patients for Potential Future Intraputamenal Transplant Study with a Dopaminergic Precursor Product; PI: Dr. Paul Larson |
| RNDP-001-02: A Phase 1b/2a Study Assessing the Safety and Efficacy of Intraputamenal Dopaminergic Stem Cell Transplants in Patients with Idiopathic Parkinson’s Disease; PI: Dr. Paul Larson |
| ANPD001-02: Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease; PI: Dr. Paul Larson |
| CT-AMT-130-01: A Phase 1/2, Randomized, Double-blind, Sham Control Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington’s Disease; PI: Dr. Paul Larson |
| The Alliance Post-Market Clinical Study: All enablIng technoLogies, bioLogics, IDS, And core spiNe produCt collection; PI Dr. Richard Chua |
| Developing a protocol for mapping intracranial hand function in human subjects; PI Dr. Martin Weinand |
Recently Closed
Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse™ Bone Graft with an Intervertebral Body Fusion Device and Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine; PI Dr. Richard Chua
A Prospective, Multi-Center, Single Arm Study to obtain “real world” clinical data and characterize the acute and long-term performance of the MICRUSFRAME and GALAXY COILS including the pulserider aneurysm neck reconstruction device for the endovascular treatment of Intracranial aneurysms; PI Dr. Michael Avery
Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson’s Disease: VISION Study; PI Dr. Julie Pilitsis